Table 1.
Patients and grafts characteristics for retrospective study
| MAC | MMAC | p | |
|---|---|---|---|
| Patient number | 24 | 34 | |
| Median age (range), years | 8 (2–42) | 14 (3–37) | 0.013a |
| ≤20 | 22 | 27 | |
| >20 | 2 | 7 | 0.367 |
| Median weight (range), kg | 26 (12–55) | 42 (12–66) | 0.005a |
| ≤45 | 22 | 23 | |
| >45 | 2 | 11 | 0.066 |
| Male sex, n (%) | 17 (71) | 25 (74) | 1 |
| Sex (donor/patient), n (%) | 0.354 | ||
| Male/male | 8 (33.3) | 8 (23.5) | |
| Male/female | 3 (12.5) | 7 (20.6) | |
| Female/male | 8 (33.3) | 16 (47.1) | |
| Female/female | 4 (16.7) | 2 (5.9) | |
| Missing data | 1 (4.2) | 1 (2.9) | |
| Diagnosis, n (%) | 0.371 | ||
| ALL | 15 (62.5) | 16 (47.1) | |
| AML or MDS | 9 (37.5) | 18 (52.9) | |
| Disease status, n (%) | 0.831 | ||
| CR1 | 15 (62.5) | 19 (55.9) | |
| CR2 | 6 (25) | 11 (34.5) | |
| ≥CR3 or NR | 3 (12.5) | 4 (11.8) | |
| Disease risk | 0.539 | ||
| Intermediate | 7 (29.2) | 7 (20.6) | |
| High | 17 (70.8) | 27 (79.4) | |
| Pretransplant therapy period | |||
| Median, days | 199 (98–1542) | 218 (80–2545) | 0.733 |
| ≤200 | 12 (50.0) | 16 (47.1) | |
| >200 | 11 (45.8) | 18 (52.9) | |
| Unknown | 1 (4.2) | 0 | 0.913 |
| No of HLA‐A, B, DR mismatched, n (%) | 0.090 | ||
| 0 | 1 (4.2) | 4 (11.8) | |
| 1 | 20 (83.3) | 19 (55.9) | |
| ≥2 | 3 (12.5) | 11 (34.5) | |
| Cell compositions in allograft | |||
| Infused nuclear cells 107/kg | 4.99 (2.70–16.24) | 4.03 (1.96–9.60) | 0.099 |
| ≤3.99 | 7 | 17 | |
| >3.99 | 17 | 17 | 0.188 |
| Infused CD34+ cells 105/kg | 2.45 (0.90–21.11) | 2.43 (1.04–5.24) | 0.548 |
| ≤2.38 | 10 | 16 | |
| >2.38 | 14 | 18 | 0.890 |
| Conditioning, n (%) | 0.002a | ||
| Bu based | 22 (91.7) | 17 (50.0) | |
| TBI based | 2 (83.3) | 17 (40.0) | |
| GVHD prophylaxis, n (%) | 0.000a | ||
| CSA/MMF/ATG | 13 (54.5) | 0 | |
| CSA/MMF/MTX | 11 (45.5) | 0 | |
| CSA/MMF | 0 | 34 (100) | |
| Follow‐up period (range), daysb | 3570 (2035–4864) | 2248 (1914–3088) | 0.039a |
a
Statistically significant.
b
Follow‐up period was for surviving patients.